Growth Disorder, Healthy
Conditions
Brief summary
This trial is conducted in Europe and United States of America (USA). The aim of this trial is to examine the bioequivalence (assessment of the expected biological equivalence of two pharmaceutical drug products with identical active ingredient) of Norditropin® versus Nutropin AQ® in healthy adult volunteers.
Interventions
DRUGsomatropin
A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* No previous exposure to recombinant human GH (growth hormone)or IGF-I (insulin-like growth factor-I) * Body mass index (BMI) 18.0-27.0 kg/m\^2 (both inclusive) * Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and electrocardiogram (ECG), as judged by the Investigator
Exclusion criteria
* The receipt of any investigational medicinal product within 1 month prior to this trial * Current or previous treatment with recombinant human growth hormone or IGF-I * Female of childbearing potential who is pregnant, breast-feeding or intends to become pregnant or is not using adequate contraceptive methods (adequate contraceptive measures as required by local law) for the duration of the trial * Known presence or history of malignancy * Diabetes mellitus * Use of pharmacologic doses of glucocorticoids * Use of anabolic steroids * History of drug or alcohol abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the serum hGH (human growth hormone) concentration-time curve (AUC0-t) | From 0 to the time of the last quantifiable concentration over a 24-hour sampling period |
| Maximum observed serum hGH concentration | Over a 24-hour sampling period |
| Area under the effect (IGF-I) curve from time 0 to the time of the last concentration (AUEC0-t) | Over a 96-hour sampling period |
| Maximum IGF-I (insulin-like growth factor-I) effect (Emax) | Over a 96-hour sampling period |
Secondary
| Measure | Time frame |
|---|---|
| The frequency of injection site reaction | From the time of injection of the trial product (day 1 and day 13) to follow-up during the two dosing periods (day 5 and day 17) |
| The frequency of adverse events (AE) and vital signs | From screening (14 days before randomisation) to follow-up period (3-21 days after randomisation) |
| Maximum IGFBP-3 (insulin-like growth factor binding protein 3) effect (Emax) | Over a 96-hour sampling period |
| Area under the effect (IGFBP-3) curve | From time 0 to the time of the last concentration (AUEC0-t) over a 96-hour sampling period |
| The frequency of abnormal hematology | From screening (14 days before randomisation) to follow-up period (20-23 days after randomisation) |
| The frequency of abnormal findings in physical examinations | From screening (14 days before randomisation) to follow-up period (20-23 days after randomisation) |
| Biochemistry laboratory parameters | From screening (14 days before randomisation) to follow-up period (20-23 days after randomisation) |
Outcome results
None listed